Arcturus Therapeutics Holdings Inc (ARCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $240.96M
Last updated: Nov 17, 2026 at 11:04 AM ET
Arcturus Therapeutics Holdings Inc (ARCT) Valuation Multiples
Arcturus Therapeutics Holdings (ARCT) trades at 7.7x sales and 1.4x book value. Its P/S of 7.7x is above its 5-year median of 3.8x. Its forward P/E is 2.5x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 2.5x |
| Price to sales | 7.7x |
| Price to book | 1.4x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 83.3% above 4.2x and its P/B is 46.2% below 2.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 7.7x | 3.8x | 4.2x |
| P/B | 1.4x | 2.2x | 2.6x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 1.9x in 2017 to 88.0x in 2020.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $6.13 | N/A | 2.0x | 0.8x |
| 2024 | $16.97 | N/A | 3.0x | 1.9x |
| 2023 | $31.53 | N/A | 5.0x | 3.0x |
| 2022 | $16.96 | 49.9x | 2.2x | 1.7x |
| 2021 | $37.01 | N/A | 78.8x | 4.3x |
| 2020 | $43.38 | N/A | 88.0x | 2.9x |
| 2019 | $10.87 | N/A | 5.8x | 6.1x |
| 2018 | $4.53 | N/A | 2.9x | 3.4x |
| 2017 | $7.95 | N/A | 1.9x | 2.4x |
| 2016 | $14.70 | N/A | N/A | 1.2x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ARCT
What is ARCT's forward P/E ratio?
Arcturus Therapeutics Holdings has a forward P/E ratio of 2.5x.
Is ARCT stock overvalued?
GNG's valuation label for ARCT is Undervalued.
What is ARCT's price to sales ratio?
Arcturus Therapeutics Holdings has a price to sales ratio of 7.7x.
ARCT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors